title: Tumor necrosis factor-alpha-mediated suppression of adipocyte apolipoprotein E gene transcription: primary role for the nuclear factor (NF)-kappaB pathway and NFkappaB p50.
abstract: The adipose tissue inflammation accompanying obesity has important consequences for adipocyte lipid metabolism, and increased adipose tissue TNFalpha plays an important role for mediating the effect of inflammation on adipocyte function. Recent studies have shown that apolipoprotein E (apoE) is highly expressed in adipose tissue where it plays an important role in modulating adipocyte triglyceride metabolism, triglyceride mass, and adipocyte size. We have previously reported that TNFalpha reduces adipocyte apoE, and the current studies were undertaken to evaluate the molecular mechanism for this regulation. TNFalpha repression of adipocyte apoE gene expression required an intact nuclear factor (NF)-kappaB binding site at -43 in the apoE promoter. Site-directed mutagenesis at this site completely eliminated TNFalpha regulation of an apoE gene reporter. TNFalpha treatment activated binding of NFkappaB p50, isolated from adipocyte nuclei, to the apoE promoter. Two structurally distinct inhibitors of NFkappaB complex activation or translocation abrogated the TNFalpha effect on the apoE gene. Using chromatin immunoprecipitation assays, we demonstrated that treatment of adipocytes with TNFalpha led to increased binding of NFkappaB p50, and decreased binding of p65 and Sp1, to this region of the apoE promoter in living cells. The key role played by increased p50 binding was confirmed by p50 knockdown experiments. Reduction of p50 expression using small interference RNA completely eliminated TNFalpha-mediated reduction of endogenous adipocyte apoE gene expression. These results establish the molecular link between adipose tissue inflammation and apoE gene expression in adipocytes. The suppression of adipocyte apoE by the proinflammatory adipose tissue milieu associated with obesity will have important downstream effects on adipocyte triglyceride turnover and content.
authors.affiliation: Department of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
authors.forename: Lili
authors.initials: L
authors.lastname: Yue
authors.forename: John W
authors.initials: JW
authors.lastname: Christman
authors.forename: Theodore
authors.initials: T
authors.lastname: Mazzone
mesh_terms: D041721:3T3-L1 Cells; D017667:Adipocytes / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics* / Q000378:metabolism; D001665:Binding Sites; D015536:Down-Regulation / Q000187:drug effects; D051379:Mice; D008954:Models, Biological; D016328:NF-kappa B / Q000502:physiology*; D052002:NF-kappa B p50 Subunit / Q000502:physiology*; D011401:Promoter Regions, Genetic; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
chemical_list: D001057:Apolipoproteins E; D016328:NF-kappa B; D052002:NF-kappa B p50 Subunit; D014409:Tumor Necrosis Factor-alpha